Nikkomycin Z

Drug Profile

Nikkomycin Z

Alternative Names: Nik Z; SP 920704

Latest Information Update: 11 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Developer University of Arizona; Valley Fever Solutions
  • Class Aminoglycosides; Antifungals; Small molecules
  • Mechanism of Action Chitin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Coccidioidomycosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Coccidioidomycosis

Most Recent Events

  • 14 Oct 2011 This programme is still active
  • 14 Oct 2011 Nikkomycin Z is available for licensing as of 14 Oct 2011. http://valleyfeversolutions.com/
  • 18 Sep 2011 Preclinical pharmacodynamics and pharmacokinetics data from in Coccidioidomycosis presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top